The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Targeting protein prenylation for cancer therapy
Open accessAbstract
Protein farnesylation and geranylgeranylation, together referred to as prenylation, are lipid post-translational modifications that are required for the transforming activity of many oncogenic proteins, including some RAS family members. This observation prompted the development of inhibitors of farnesyltransferase (FT) and geranylgeranyl-transferase 1 (GGT1) as potential anticancer drugs. In this Review, we discuss the mechanisms by which FT and GGT1 inhibitors (FTIs and GGTIs, respectively) affect signal transduction pathways, cell cycle progression, proliferation and cell survival. In contrast to their preclinical efficacy, only a small subset of patients responds to FTIs. Identifying tumours that depend on farnesylation for survival remains a challenge, and strategies to overcome this are discussed. One GGTI has recently entered the clinic, and the safety and efficacy of GGTIs await results from clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This modification was the target of an active pipeline of farnesyltransferase inhibitors and yielded preclinical responses however limited responses in clinical trials12.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862 · cited 1×
“162 ), which activates CDK4 and other kinases and ultimately leads to inhibitory phosphorylation of RB, thus permitting the G1/S transitio”
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083 · cited 1×
“AKT phosphorylates and inactivates TSC1–TSC2, causing activation of RHE”
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
PROTEIN PRENYLATION: Molecular Mechanisms and Functional Consequences
Zhang, F. L., & Casey, P. J. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.001325 · Cited by 2,018
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome
Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., Erdos, M. R., Robbins, C. M., Moses, T. Y., Berglund, P., et al. (2003) · Nature · doi:10.1038/nature01629 · Cited by 1,990
All ras proteins are polyisoprenylated but only some are palmitoylated
Hancock, J. F., Magee, A. I., Childs, J. E., & Marshall, C. J. (1989) · Cell · doi:10.1016/0092-8674(89)90054-8 · Cited by 1,775
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555 · cited 1×
“AKT phosphorylates and inactivates TSC1–TSC2, causing activation of RHE”
Genomic analysis of metastasis reveals an essential role for RhoC
Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000) · Nature · doi:10.1038/35020106 · Cited by 1,444
Research works printed but not linked: 1
- Berndt, N. & Sebti, S. M. Measuring protein farnesylation and geranylgeranylation and using prenyltransferase inhibitors as chemical probes and anticancer agents. Nature Protoc. (in the press).
Cited by
Sorted by citations
Items 601–622 of 622
Yang, T., Ye, L., Xie, P., Song, T., Chen, J. X., Zhao, H., Liu, Z., Chen, X., Ding, J., Ding, X., et al. (2026) · Advanced Science · doi:10.1002/advs.75554
Renaissance of farnesyltransferase inhibitors in cancer
Tı́már, J., Hegedűs, B., & Baranyi, M. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08298-5
“Besides these two FTIs, BMS-214,662 and L-778,123 have been also tested clinically without success [13, 16].”
Exploring the Isoprenoid Biosynthesis Pathway’s Role in Oncogenic Viruses
Blaha, L. N., Neighbors, J. D., Sandeep, R., Kondaka, A., & Hohl, R. J. (2026) · Viruses · doi:10.3390/v18060637
“These limitations suggest that future strategies should focus on combination therapeutic approaches such as simultaneous FTase and GGTase inhibition or synergistic targeting of upstream metabolic pathways with immunotherapies to overcome resistance mechanisms [103,104].”
Bhansali, R. S., Long, J. S., Pölönen, P., Isobe, T., Wang, S., Zhang, S., Geng, Z., Tausif, A., Antopia, M. C., Aboreden, N. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.29.733236
A multipurpose probe for identification and mechanistic analysis of prenylation inhibitors
Yehia, R., Giladi, M., & Haitin, Y. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2700494
Mapperley, C., Georges, E., Azar, A. A., Kabayama, Y., Lawson, H., Kuciński, I., George, D., Campos, J., Fyfe, C., Durko, J., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec3399
“Extensive investigation of mevalonate pathway inhibitors has demonstrated their potential in a variety of cancers ( 43 , 45 ) including AML ( 42 , 90 ), resulting in clinical trials across a spectrum of blood malignancies ( 91 – 95 ).”
InfluentialLou, J., Zhang, D., & Wang, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1907367
Prenylation: A key regulatory point in tumor metabolism and a potential therapeutic target
Su, Z., Liu, F., Lin, Y., Hong, X., Cui, H., Sun, R., & Qi, B. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112880
Emergence of Rheb as a promising therapeutic target in the amelioration of diabetes
Dey, N. (2026) · Academia molecular biology and genomics. · doi:10.20935/acadmolbiogen8500
Catalytic properties of the integral membrane RAS protease Rce1
Dongen, D. V., Collette, A. M., Diver, M. M., & Long, S. B. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113525
“Interest-ingly, release of the prenylated product is the rate-limiting step for prenylation by FTase and likely GGTase-I, where dissociation of the prenylated product limits turnover (14, 83, 84).”
InfluentialBindingDB Entry 50045098: Development of synthetic lethality anticancer therapeutics.
BindingDB (2016) · UC San Diego · doi:10.7270/q2vd714c
BindingDB Entry 50021933: α-Amino bisphosphonate triazoles serve as GGDPS inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q2j67nks
BindingDB Entry 50000629: Discovery of Novel KRAS-PDEδ Inhibitors by Fragment-Based Drug Design.
BindingDB (2019) · UC San Diego · doi:10.7270/q2cz39mm
BindingDB Entry 50000422: Structural Biology-Inspired Discovery of Novel KRAS-PDEδ Inhibitors.
BindingDB (2019) · UC San Diego · doi:10.7270/q2571fdq
BindingDB (2020) · UC San Diego · doi:10.7270/q2hd7zn5
BindingDB Entry 50019371: Advances in the development of Rho GTPase inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q2wh2vcw
Metadata
- Authors
- Berndt, N., Hamilton, A. D., & Sebti, S. M.
- Affiliations
- Moffitt Cancer Center (US)
- University of Oxford (GB)
- ORCID
- Hamilton, Andrew D.
- Venue
- Nature Reviews Cancer
- Published
- 2011-10-24
- Volume
- 11
- Issue
- 11
- Pages
- 775-791
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4037130
- OpenAlex
- W2002252224
- Cited by
- 614
- References
- 221
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 20 · 2023: 42 · 2022: 34 · 2021: 52 · 2020: 59 · 2019: 46 · 2018: 42 · 2017: 46 · 2016: 52 · 2015: 47 · 2014: 48 · 2013: 44 · 2012: 30
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA098473, U19CA067771, CA067771, R01CA098473)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- protein prenylation, farnesylation, geranylgeranylation, farnesyltransferase inhibitors, signal transduction, cell cycle progression, tumor cell survival, anticancer drug development, clinical trial results
- MeSH terms
- Ras Homolog Enriched in Brain Protein, Animals, Antineoplastic Agents, Cell Cycle, Cell Survival, Enzyme Inhibitors, Humans, Neoplasms, Neuropeptides, Signal Transduction, Randomized Controlled Trials as Topic, Protein Prenylation, Alkyl and Aryl Transferases, Monomeric GTP-Binding Proteins, Cell Proliferation, Farnesyltranstransferase, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
